TABRECTA
Generic: capmatinib
- NDC
- 0078-0709
- RxCUI
- 2362234
- Route
- ORAL
- ICD-10 indication
- C34.9
Affordability Check
How much will you actually pay for TABRECTA?
In 30 seconds, see every legitimate way to afford TABRECTA — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.
About TABRECTA
What is this medication?
Tabrecta is a prescription medicine used to treat adults with a specific type of lung cancer called non-small cell lung cancer (NSCLC). It is specifically indicated for patients whose cancer has spread to other parts of the body, which is known as metastatic disease. This medication is used only when the cancer cells have a particular genetic biomarker or abnormality called a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.
The drug belongs to a class of medications known as kinase inhibitors and works by targeting the MET protein. In patients with this specific genetic mutation, the MET protein can become overactive, which helps the cancer cells grow and spread throughout the body. By blocking the activity of this protein, the medication can help to slow down or stop the growth of the tumors. It is taken orally in tablet form and is prescribed after a healthcare professional confirms the presence of the mutation using a specialized diagnostic test.
Copay & patient assistance
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.
External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.
Compare pricing elsewhere
RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.
Cost Plus Drug Company
Mark Cuban's transparent-pricing pharmacy — manufacturer cost + 15% markup + $5 dispensing fee. No insurance needed. Search alphabetically for capmatinib.
Browse Cost Plus medications →
GoodRx
Compare local pharmacy prices with GoodRx coupons. Use the price with your insurance or without — whichever is cheaper.
Lookup TABRECTA →
NeedyMeds
Independent nonprofit directory of patient assistance programs, copay cards, and charity co-pay foundations.
Search for capmatinib →
RxAssist
PAP directory maintained by Volunteers in Health Care at Brown University. Free, no ads.
Search PAPs →
We deep-link because transparency helps patients. None of these partners pay RxCopays.
Conditions we've indexed resources for
Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.
Medicare Part D coverage
How TABRECTA appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-08-31).
Covered by plans
39%
2,143 of 5,499 plans
Most common tier
Tier 5
On 79% of covering formularies
Prior authorization required
99%
of covering formularies
| Tier | Formularies on this tier | Share |
|---|---|---|
| Tier 1 (preferred generic) | 59 | 18% |
| Tier 2 (generic) | 2 | 1% |
| Tier 4 (non-preferred brand) | 7 | 2% |
| Tier 5 (specialty) | 259 | 79% |
| Tier 6 | 1 | 0% |
Step therapy: 0% of formularies
Quantity limits: 83% of formularies
Coverage breadth: 328 of 65 formularies
How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).
Prior authorization & coverage
| Payer | PA | Step therapy | Copay tier |
|---|---|---|---|
— Medicare Part D | — | — | — |
Related drugs
EVEROLIMUS
Treats same condition · Everolimus
AVMAPKI FAKZYNJA CO-PACK
Treats same condition · avutometinib potassium and defactinib hydrochloride
Fludeoxyglucose F18
Treats same condition · Fludeoxyglucose F18
Portrazza
Treats same condition · necitumumab
Pilocarpine Hydrochloride
Treats same condition · Pilocarpine Hydrochloride
TEPADINA
Treats same condition · THIOTEPA
AVGEMSI
Treats same condition · Gemcitabine
CLENPIQ
Treats same condition · SODIUM PICOSULFATE, MAGNESIUM OXIDE, and ANHYDROUS CITRIC ACID
Niva Thyroid
Treats same condition · thyroid, porcine
Kisunla
Treats same condition · donanemab-azbt
How this page is sourced
- Drug identity verified against openFDA NDC Directory.
- Label text (when shown) originates from NLM DailyMed.
- Copay and assistance URLs verified periodically; if you hit a broken link, tell us.